PegBio Co Ltd (2565) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of PegBio Co Ltd HK$1.23, price HK$5.21, upside -76.4%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PegBio Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
16‑month range HK$4.96 – HK$74.65 · fair‑value band HK$0.8100 – HK$1.53 · the HK$5.21 price screens above the HK$1.23 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow PegBio Co in your weekly email
Every Wednesday you see whether PegBio Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity.
Show more
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
Stock analysis
PegBio Co Ltd (2565) currently trades at HK$5.21, while our model-based Fair Value estimate is HK$1.23, 76.4% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.
Scenario range: HK$0.8100 (bear) to HK$1.53 (bull), the price of HK$5.21 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
PegBio Co Ltd reported revenue of 0 CNY in FY2025 versus 0 CNY in FY2022. Reported net income was −208M CNY in FY2025.
Key figures
Market cap HK$2.2B (≈ $284M) · EPS (TTM) HK$−0.2500 · Return on equity −82.4% · Return on assets (EBIT) −77.8% · Free cash flow −HK$156M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 93% below its 52-week high and 5% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −76%, 2565 screens richer than that median.
Fair Value models
Bear HK$0.8100Fair Value HK$1.23Bull HK$1.53
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 633 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Above median
Fair Value upside−76.4% · Bottom 25%
Profitability
Return on assets−31.5% · Bottom 25%
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "PegBio Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2565
Frequently asked questions
Is PegBio Co Ltd (2565) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$1.23 versus a price of HK$5.21, about −76% upside (overvalued).
What is the fair value of 2565?
Our model-based fair value for PegBio Co Ltd is HK$1.23 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$5.21.
What is the quality score of 2565?
PegBio Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PegBio Co Ltd (2565)?
Our model-based price target is the fair value of HK$1.23 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.8100, optimistic scenario HK$1.53. It is a calculation from audited fundamentals, not an analyst target.
What is the PegBio Co Ltd stock forecast for 2026?
Our models put fair value at HK$1.23, about −76% upside versus a price of HK$5.21 (overvalued). Cautious scenario HK$0.8100, optimistic scenario HK$1.53. The calculation is refreshed regularly with new filings.
What is the intrinsic value of PegBio Co Ltd (2565)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PegBio Co Ltd it is HK$1.23 per share (as of Sep 27, 2026), against a price of HK$5.21. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is PegBio Co Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2565 trades above its calculated fair value: price HK$5.21, fair value HK$1.23, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2565?
No. The price is what the market pays today (HK$5.21); the fair value is what the company's own numbers justify (HK$1.23). For PegBio Co Ltd the two are HK$3.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is PegBio Co Ltd worth?
The market values PegBio Co Ltd at about HK$2.2B (market capitalisation, as of Sep 27, 2026). Per share that is HK$5.21; our models calculate a fair value of HK$1.23 per share.
What do the bullish and bearish scenarios say about 2565?
Our models span a range for PegBio Co Ltd: cautious scenario HK$0.8100, base HK$1.23, optimistic HK$1.53 per share (as of Sep 27, 2026, price HK$5.21). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PegBio Co Ltd (2565)?
Balance-sheet figures for PegBio Co Ltd (as of Sep 27, 2026): return on equity −82.4%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 2565 from its 52-week high?
PegBio Co Ltd trades at HK$5.21, about 93% below its 52-week high of HK$74.65 and 5% above the low of HK$4.96 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.23 is for.
Which stocks are comparable to PegBio Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PegBio Co Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$5.21, calculated fair value HK$1.23 (−76%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2565 calculated?
We run PegBio Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$1.23, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. PegBio Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PegBio Co Ltd (2565)?
The closing price on Sep 30, 2026 was HK$5.21. Our model-based fair value is HK$1.23, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PegBio Co Ltd right now?
The price sits above even our optimistic bull case (HK$1.53). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.8100 to HK$1.53) leaves room in how you read the outcome.
Key figures of PegBio Co Ltd
How large is the market capitalisation of PegBio Co Ltd (2565)?
The market capitalisation of PegBio Co Ltd is HK$2.2B (≈ $284M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of PegBio Co Ltd (2565)?
Earnings per share at PegBio Co Ltd are HK$−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of PegBio Co Ltd (2565)?
The return on equity (ROE) of PegBio Co Ltd is −82.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PegBio Co Ltd (2565)?
On an EBIT basis the return on assets of PegBio Co Ltd is −77.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does PegBio Co Ltd (2565) generate?
The free cash flow of PegBio Co Ltd is −HK$156M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch PegBio Co Ltd in the live analysis
One click puts PegBio Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
